09997126

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1613sxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced
NEWS	15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:06:21 ON 02 NOV 2003

=> fil reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 20:06:27 ON 02 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 OCT 2003 HIGHEST RN 611606-12-3
DICTIONARY FILE UPDATES: 31 OCT 2003 HIGHEST RN 611606-12-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

```
=> s atorvastatin hemi-calcium
           10 ATORVASTATIN
         5329 HEMI
        76661 CALCIUM
L1          2 ATORVASTATIN HEMI-CALCIUM
              (ATORVASTATIN(W)HEMI(W)CALCIUM)

=> fil caplus
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.06	13.27

FILE 'CAPLUS' ENTERED AT 20:06:44 ON 02 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Nov 2003 VOL 139 ISS 19
FILE LAST UPDATED: 31 Oct 2003 (20031031/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1 full
L2         127 L1

=> s l2 and form VIII
       1308808 FORM
         98646 VIII
            91 FORM VIII
                 (FORM(W)VIII)
L3           1 L2 AND FORM VIII

=> d l3 ibib abs hitstr

L3   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2002:428715  CAPLUS
DOCUMENT NUMBER:          137:10960
TITLE:                    Novel crystal forms of atorvastatin hemicalcium and
                          processes for their preparation as well as novel
                          processes for preparing other forms
INVENTOR(S):              Aronhime, Judith; Lidor-Hadas, Ramy; Niddam, Valerie;
                          Lifshitz, Revital; Ishai, Eti; Sambursky, Guy
PATENT ASSIGNEE(S):       Teva Pharmaceutical Industries Ltd., Israel; Teva
                          Pharmaceuticals USA, Inc.
SOURCE:                   PCT Int. Appl., 68 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2002043732      A1   20020606       WO 2001-US44636  20011129
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002017927      A5   20020611       AU 2002-17927    20011129
     US 2002183378      A1   20021205       US 2001-997126   20011129
     NO 2003002425      A    20030725       NO 2003-2425     20030528
PRIORITY APPLN. INFO.:                  US 2000-250072P  P  20001130
                                        US 2001-267897P  P  20010209
                                        US 2001-281872P  P  20010405
                                        US 2001-312144P  P  20010813
                                        US 2001-326529P  P  20011001
                                        WO 2001-US44636  W  20011129
AB   The present invention provides novel forms of atorvastatin designated
     Forms VI, VIII, IX, X, XI and XII and novel processes for their prepn. as
     well as processes for prepg. atorvastatin Forms, I, II, IV, V and
     amorphous atorvastatin.  For example, 1.0 g (1.59x10-3 mole) of
     [R-(R*,R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dioxane-5-(1-methylethyl)-3-
     phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester
     was suspended in a 90% aq. soln. of acetic acid (10 mL) and heated to
```

50.degree.. The solvent was evapd. and the traces of acetic acid were removed by azeotropic distn. with toluene to obtain an oil with some toluene. This oil was dissolved in EtOH (10 mL) and water (2 mL) and then 5.5 equiv (8.4x10-3 mole, 622 mg) of Ca(OH)2 and tetra-Bu ammonium bromide (5%) were added. The reaction mixt. was heated at 50.degree. until the reaction was complete. Then a hot filtration was done under vacuum to remove the excess of Ca(OH)2 and the reaction mixt. was cooled to room temp. To this soln. water (50 mL) was added while stirring. The white ppt. was stirred at room temp. overnight, filtered under vacuum and dried at 65.degree. to give 145 mg (16%) of atorvastatin hemicalcium salt **Form VIII**.

IT **134523-03-8P**, Atorvastatin hemicalcium
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of crystal forms of atorvastatin hemicalcium and its hydrate and solvates)

RN 134523-03-8 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (.beta.R,.delta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

IT **344423-98-9P**, Atorvastatin hemicalcium trihydrate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of crystal forms of atorvastatin hemicalcium and its hydrate and solvates)

RN 344423-98-9 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), trihydrate, (.beta.R,.delta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

●3/2 H_2O

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09997126

Welcome to STN International! Enter x:x

LOGINID:ssspta1613sxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced
NEWS	15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:17:05 ON 02 NOV 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 20:17:12 ON 02 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

09997126

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 OCT 2003 HIGHEST RN 611606-12-3
DICTIONARY FILE UPDATES: 31 OCT 2003 HIGHEST RN 611606-12-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09997126.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 20:17:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      7 TO ITERATE

100.0% PROCESSED       7 ITERATIONS                                 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            7 TO      298
PROJECTED ANSWERS:               5 TO      234

L2             5 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 20:17:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     98 TO ITERATE

100.0% PROCESSED      98 ITERATIONS                               65 ANSWERS
SEARCH TIME: 00.00.01

L3            65 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   148.15     148.36

FILE 'CAPLUS' ENTERED AT 20:17:41 ON 02 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Nov 2003  VOL 139 ISS 19
FILE LAST UPDATED: 31 Oct 2003  (20031031/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3 full
L4          1020 L3
```

09997126

=> s l4 and peaks?
        146370 PEAKS?
L5   3 L4 AND PEAKS?

=> d l5 1-3 ibib abs hitstr

L5   ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:678785 CAPLUS
DOCUMENT NUMBER: 139:202534
TITLE: Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms I, VIII and IX
INVENTOR(S):   Tessler, Limor; Aronhime, Judith; Lifshitz-Liron, Revital; Maidan-Hanoch, Dalia; Hasson, Nir
PATENT ASSIGNEE(S):   Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 34 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070702	A1	20030828	WO 2003-US5384	20030219

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-357181P P 20020215
                        US 2002-425325P P 20021112

AB Solid cryst. atorvastatin hemi-calcium, and solvates, which are characterized by a powder X-ray diffraction pattern having **peaks** at 9.3 and 9.5+0.2 degrees two-theta are prepd.

IT **134523-03-8**, Atorvastatin hemi-calcium
    RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (prepn. of novel crystal forms of atorvastatin hemi-calcium)

RN 134523-03-8 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (.beta.R,.delta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:4785 CAPLUS
DOCUMENT NUMBER: 134:202384
TITLE: A Four-Column Parallel Chromatography System for Isocratic or Gradient LC/MS Analyses
AUTHOR(S): van Pelt, Colleen K.; Corso, Thomas N.; Schultz, Gary A.; Lowes, Stephen; Henion, Jack
CORPORATE SOURCE: Advanced BioAnalytical Services Inc., Ithaca, NY, 14850, USA
SOURCE: Analytical Chemistry (2001), 73(3), 582-588
CODEN: ANCHAM; ISSN: 0003-2700
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A novel approach to parallel liq. chromatog./tandem mass spectrometry (LC/MS/MS) analyses for pharmacokinetic assays and for similar quant. applications is presented. Modest modifications render a conventional LC/MS system capable of analyzing samples in parallel. These modifications involve the simple incorporation of three valves and four LC columns into a conventional system composed of one binary LC pumping system, one autosampler, and one mass spectrometer. An increase in sample throughput is achieved by staggering injections onto the four columns, allowing the mass spectrometer to continuously analyze the chromatog. window of interest. Using this approach, the optimized run time is slightly greater than the sum of the widths of the desired **peaks**. This parallel chromatog. unit can operate under both gradient and isocratic LC conditions. To demonstrate the utility of the system, atorvastatin, five of its metabolites, and their deuterated internal stds. (IS) were analyzed using gradient elution chromatog. conditions. The results from a pre-study assay evaluation (PSAE) tray of stds. and quality control (QC) samples from extd. spiked human plasma are presented. The relative std. deviation and the accuracy of the QC samples did not exceed 8.1% and 9.6%, resp., which is well within the acceptance criteria of the pharmaceutical industry. For this particular anal., the parallel chromatog. system decreased the overall run time from 4.5 to 1.65 min and, therefore, increased the overall throughput by a factor of 2.7 in comparison to a conventional LC/MS/MS anal. method.

IT **134523-00-5**, Atorvastatin
RL: ANT (Analyte); BPR (Biological process); BSU (Biological study,

unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process)
(four-column parallel chromatog. system for isocratic or gradient LC/MS analyses)

RN 134523-00-5 CAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (.beta.R,.delta.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **214217-86-4**, 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-4-[[(2-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (.beta.R,.delta.R)- **214217-88-6**
RL: ANT (Analyte); BSU (Biological study, unclassified); MFM (Metabolic formation); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative)
(four-column parallel chromatog. system for isocratic or gradient LC/MS analyses)

RN 214217-86-4 CAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-4-[[(2-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (.beta.R,.delta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 214217-88-6 CAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-4-[[(4-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (.beta.R,.delta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:8790 CAPLUS
DOCUMENT NUMBER: 130:191350
TITLE: Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, o-hydroxyatorvastatin, and p-hydroxyatorvastatin in human, dog, and rat plasma
AUTHOR(S): Bullen, William W.; Miller, Ronald A.; Hayes, Roger N.
CORPORATE SOURCE: Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SOURCE: Journal of the American Society for Mass Spectrometry (1999), 10(1), 55-66
CODEN: JAMSEF; ISSN: 1044-0305
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A liq. chromatog./mass spectrometric method to quantitate atorvastatin (AT) and its active metabolites o-hydroxy (o-AT) and p-hydroxy (p-AT) atorvastatin in human, dog, and rat plasma was validated. The method consisted of washing plasma samples at high pH with Et2O and subsequently extg. the analytes and 2 internal stds., [d5]-AT and [d5]-o-A, from acidified plasma with Et2O. The org. layer was evapd. to dryness and the residue reconstituted in NH4OAc (20 mM, pH 4.0)-MeCN-iso-PrOH (60:40:1). Chromatog. sepn. of analytes was achieved by using a YMC J'Sphere H80 (C-18) 150 x 2 mm, 4 .mu.m particle size, column with a mobile phase consisting of MeCN-0.1% HOAc (70:30). Analytes were detected by using tandem mass spectrometry. Sample introduction and ionization were by electrospray ionization in the pos. ion mode. The method proved suitable for routine quantitation of AT, o-AT, and p-AT over the concn. range 0.250-25.0 ng/mL. Approx. retention time ranges of p-AT, o-AT, [d5]-o-AT, AT, and [d5]-AT were 2.27, 3.36, 3.54, 4.12, and 4.65 min, resp. No **peaks** interfering with quantitation were obsd. throughout the validation processes. Mean recoveries of AT, o-AT, and p-AT from plasma ranged 100%-107%, 70.6%-104%, and 47.6%-85.6%, resp. Mean recoveries of the [d5]-AT and [d5]-o-AT internal stds. ranged 98.0%-99.9% and 97.3%-97.9%, resp. Interassay precision, based on the percent relative

deviation for replicate quality controls for AT, o-AT, and p-AT, was .ltoreq.7.19%, 8.28%, and 12.7%, resp. Interassay accuracy for AT, o-AT, and p-AT was .+-.10.6%, 5.86%, and 15.8%, resp. AT, o-AT, and p-AT in human, dog, and rat plasma quality control samples were stable to 3 freeze-thaw cycles. AT, o-AT, and p-AT were stable when frozen for 127, 30 and 270 days in human, dog, and rat plasma quality control samples, resp. Human plasma quality control samples contg. AT, o-AT, and p-AT were stable for .gtoreq.4 days at ambient room temp. and 37.degree.. The lower limit of quantitation for all the analytes was 0.250 ng/mL for a 1.0-mL sample aliquot.

IT **134523-00-5**, Atorvastatin
RL: ANT (Analyte); ANST (Analytical study)
(detn. of atorvastatin, o-hydroxyatorvastatin, and p-hydroxyatorvastatin in human, dog, and rat plasma by HPLC and tandem mass spectrometry)

RN 134523-00-5 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (.beta.R,.delta.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **214217-86-4**, o-Hydroxyatorvastatin **214217-88-6**, p-Hydroxyatorvastatin
RL: ANT (Analyte); BSU (Biological study, unclassified); MFM (Metabolic formation); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative)
(detn. of atorvastatin, o-hydroxyatorvastatin, and p-hydroxyatorvastatin in human, dog, and rat plasma by HPLC and tandem mass spectrometry)

RN 214217-86-4 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-4-[[(2-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (.beta.R,.delta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 214217-88-6 CAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-4-[[(4-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (.beta.R,.delta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT